StreetAlpha.app
Home › Stocks › ACOG

Alpha Cognition Inc. (ACOG)

$9.00
▲ +1.69%
LAST CLOSE · NOV 20

Alpha Cognition develops and sells ZUNVEYL, an oral tablet for Alzheimer's disease. It last closed at $9.00 on Nov 20, up 1.69% on the day. For the quarter ended Sep 2026, ACOG reported EPS of -$0.35 on revenue of $7.8M, with revenue up 173.8% from a year ago. Over the last 12 months ACOG insiders bought $8.3M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ACOG in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACOG.

Key Stats

Last 12 months
Results
Revenue
$20.2M
Net income
−$28.1M
−139.2% margin
EPS (diluted)
−$1.30
Free cash flow
−$30.8M
−152.7% margin
Valuation
Market cap
$198.4M
22.0M shares
P/E
–
No P/E while losing money
Price to sales
9.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$37.8M
At Sep 30
Shareholder equity
$49.3M
Shares outstanding
22.0M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$13.8M−$13.8MFY2023FY2024: −$14.8M−$14.8MFY2024FY2025: −$20.7M−$20.7MFY2025

From ACOG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Mar 26
2026 · next date not set yet
Reported EPS
-$0.35
Quarter ended Sep 2026
Year ago EPS
-$0.29
Same quarter last year
Revenue
$7.8M
+173.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.53Dec '24Mar 2025: -$0.11Mar '25Jun 2025: -$0.82Jun '25Sep 2025: -$0.29Sep '25Dec 2025: -$0.29Dec '25Mar 2026: -$0.32Mar '26Jun 2026: -$0.40Jun '26Sep 2026: -$0.35Sep '26Latest -$0.35
Revenue by quarter
Mar 2025: $2.9MMar '25Jun 2025: $1.7MJun '25Sep 2025: $2.8MSep '25Dec 2025: $2.8MDec '25Mar 2026: $3.5MMar '26Jun 2026: $6.1MJun '26Sep 2026: $7.8MSep '26Latest $7.8M
How ACOG moved after its last 1 report
Average move the session after a report ±4.9%
Mar 26, 2026After the close−4.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ACOGStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ACOG
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACOG

Technical Analysis

ACOG · as of the Nov 20 close · updated each morning
Uptrend

The stock is 5% above its 20 day and 4% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the swing low (Sep 1) at $8.92, and the nearest resistance the swing high (Nov 9) at $9.19.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$10.1452 week high+12.7%
$9.21Pivot R1+2.3%
$9.19Swing high (Nov 9)+2.1%
$9.00Last close
$8.92Swing low (Sep 1)−0.9%
$8.89Pivot−1.2%
$8.71100 day average−3.2%
$8.69Pivot S1−3.4%
$8.6650 day average−3.8%
$8.5620 day average−4.9%
$7.38200 day average−18.0%
$4.5052 week low−50.0%
Indicators
RSI (14)56.48Middle of its rangeNeutral
MACD-0.03Above its signal lineBullish
Stochastic74.8Middle of its rangeNeutral
ADX (14)12.7No clear trend
Williams %R-12.8Oversold below −80, overbought above −20Overbought
CCI (20)79.2Oversold below −100, overbought above 100Neutral
Rate of change+8.6%Change over 10 sessionsBullish
ATR (14)$0.53Typical daily range, 5.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ACOG

What happened before

See how ACOG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for ACOGHow many large options trades hit ACOG, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ACOG Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲24 buying vs 10 selling
  • ▲Held by funds +0.6 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4226+61.5%
In funds' top 1031+200.0%
Held by funds48.7%48.1%+0.6 pts
New / increased18 / 61 / 7+200.0%
Reduced / sold out8 / 24 / 0+150.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACOG institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACOG Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$8.3M27 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $2.1M between Jul 22 and Aug 21.
2026-02 bought $1.0M2026-03 bought $1.1M2026-05 bought $791K2026-06 bought $1.3M2026-07 bought $1.6M2026-08 bought $519K2026-09 bought $1.3M2026-10 bought $740KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 23Opaleye Management Inc.10% ownerBuy32,090$8.28$266K
Oct 16Opaleye Management Inc.10% ownerBuy36,940$8.35$309K
Oct 1Opaleye Management Inc.10% ownerBuy19,050$8.69$166K
Sep 25Opaleye Management Inc.10% ownerBuy31,763$8.53$271K
Sep 16Opaleye Management Inc.10% ownerBuy123,918$8.57$1.1M
Aug 21Robert James WillsDirectorBuy10,000$9.62$96K
Every insider buy and sale for ACOG over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACOG insider trades →

From SEC Form 4 filings by ACOG's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACOG is in one of them and how their past ACOG trades turned out.

ACOG in the AI portfolios
Loading…

ACOG News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACOG in an article yet. Here's the latest on the wider market.

ACOG in the news

About Alpha Cognition

Alpha Cognition is a biopharmaceutical company based in Grapevine, Texas, that develops treatments for neurodegenerative diseases, with a focus on Alzheimer's disease. Its main product is ZUNVEYL, an oral tablet for mild to moderate dementia of the Alzheimer's type. The company sells ZUNVEYL to nursing homes that care for Alzheimer's patients, working with physicians, pharmacies and pharmacy benefit managers to expand access. It also has earlier stage programs and has licensed ZUNVEYL rights in parts of Asia, Australia and New Zealand.

Headquarters
Grapevine, TX